Venetoclax addition improves survival in chemotherapy-ineliglible patients with AML

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Jun 22 / Springer Healthcare

Venetoclax addition improves survival in chemotherapy-ineliglible patients with AML

The University of Texas MD Anderson Cancer Center, Houston, USA

Haematology EHA-2020

Description

Courtney DiNardo discusses the phase 3 VIALE-A study supporting the addition of venetoclax to azacitidine as a new standard of care option for the first-line treatment of acute myeloid leukaemia patients who are ineligible for intensive chemotherapy.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.